24 pharmaceutical companies released a quarterly report to predict that more than half of the epidemic situation caused a change in performance

24 pharmaceutical companies released a quarterly report to predict that more than half of the epidemic situation caused a change in performance
As of the afternoon of April 1st, sauna and Yewang. According to the statistics of Flush Flush, 24 pharmaceutical and biological companies released the first quarter notice, 13 of which said that the new coronary pneumonia epidemic situation affected the performance mechanism.Among them, the performance of Kangtai Biology, Watson Bio, and Shutaishen fell by more than 100%; Jiu’an Medical, Yiling Pharmaceuticals and others had pre-increased performance, and Jiu’an Medical turned losses into profit.Increased sales of epidemic-related products from 5 companies led to a substantial increase in performance. Among the 24 companies that announced their first-quarter results, 11 companies had increased their performance and even turned losses into profit.Five companies including Jiu’an Medical, Yangpu Medical, Yiling Pharmaceutical, Wanfu Biological, and Wohua Pharmaceutical made it clear that sales of products related to the epidemic have increased, and performance is expected to increase.Among them, Jiu’an Medical expects a net profit of 40 million yuan to 60 million yuan, with the highest annual growth rate of 269.89%, turning losses into profits.After the outbreak of the new crown epidemic, the frontal temperature gun became the most convenient and cheap weapon for screening public body temperature abnormalities in major public places.For this reason, the Even gun has also become another temporary epidemic prevention material after the mask.Jiu’an Medical therefore received a large number of orders and insisted on not raising prices. By mid-March, the daily output of the temperature gun reached 1.50,000 pcs. It is expected to ship immediately every day, basically zero inventory.In the first quarter performance forecast, Jiu’an Medical weighed and reported the timetable. The company quickly responded to internal public health and epidemic prevention needs, resumed production in advance, and actively expanded production capacity. The temperature measurement series represented by Jiu’an (iHealth) temperature gunsSignificant sales growth has a positive impact on improving the company’s current performance.In addition, the company reports that it has already begun exporting thermometers to foreign countries to help prevent and control the global epidemic.Wohua Pharmaceutical’s performance in the first quarter of this year also increased, and the net profit attributable to shareholders of listed companies was 3654.480,000 yuan-4,466.580,000 yuan, an annual increase of 170% -230%.Volvo Pharmaceuticals’ substantial growth has also benefited from the sharp increase in sales of epidemic-related products.The recommended medicines and heat-clearing and detoxifying drugs of Wohua Pharmaceuticals in the national epidemic situation of the producing countries are Fangfengtongsheng pills, orange-red pear cream, Iris cold granules, antiviral oral liquid, etc. Under the replacement of protection, Wohua Medical Organization will work overtime.The production of such drugs has contributed a new growth point to sales revenue in the first quarter.Yiling Pharmaceutical’s Lianhua Qingwen product has been used for constipation clinically since the outbreak. The paper published by Zhong Nanshan’s team is also clear that it has the effect of inhibiting the replication of new coronavirus cells.Affected by the above benefits, Yiling Pharmaceutical’s revenue in the first quarter of Lianhua Qingwen’s products increased over the same period of the previous year, and the company’s profit in the first quarter.3.3 billion cents-4.$ 6.1 billion, an annual increase of 50% -60%.Yangpu Medical’s epidemic-related automatic capping machines, nucleic acid detection blood collection tubes, sample preservation solutions, swabs, masks and other epidemic-related products are expected to increase by approximately 52 million yuan from the same period last year, which will contribute the most to the first quarter of this year.Yangpu Medical expects net profit attributable to shareholders of listed companies to increase by 120% -150% in the first quarter.During the epidemic period, Wanfu Biotechnology accelerated the development of new coronavirus testing reagents and successfully passed the national emergency approval channel. Wanfu Biotechnology used the rapid growth of epidemic-related testing product sales revenue to boost the company’s stable growth. It is expected that the first quarter net profit will increase by 25% -35%.Affected by the epidemic, 11 companies expected to increase their performance in 24 companies, 13 companies made it clear that the company’s performance was affected by the epidemic, including Huaren Pharmaceutical, Tomson Baker and 11 companies expected to replace performance.The performance of Watson Bio and Shu Taishen is serious, and it is expected to turn from profit to loss.Sauna and Yewang combing found that these enterprises were mainly responsible for logistics, personnel return to work was blocked due to the outbreak of the epidemic, and hospital diagnosis and treatment services were reduced, which had a certain impact on the company’s first quarter supplies, procurement, pharmaceutical production, and sales.Some vaccine companies suffered severely.Kangtai Biology estimates that the net profit attributable to shareholders of listed companies will be at least 85% -100% in the first quarter of this year; the net profit attributable to shareholders of listed companies will be -1800 trillion to -23 million yuan, compared with 3873 last year.320,000 yuan, the highest in a year is 159.38%.Both companies said in the reasons for the decline in performance that due to the epidemic, vaccine sales fell, impacting the first quarter results.Watson Bio pointed out that during the epidemic, most of the vaccination clinics suspended their vaccination. Due to the suspension of transportation and logistics, the distribution of vaccine products also encountered great difficulties.The recent outbreak of new coronavirus infection pneumonia may continue to deteriorate, and the company’s international sales business is facing challenges. If the overseas epidemic continues to be serious and severe, the company still has the risk of purchasing some imported raw materials.The company will conduct a comprehensive follow-up and evaluation of domestic and overseas epidemic situations, timely adjust planned operation arrangements, adopt various measures to ensure the safe and orderly development of production and operation, and strive to reduce the adverse impact of the epidemic situation on the company’s production and operation.Kangtai Biological is more optimistic that the internal epidemic situation is controlled, the vaccine is gradually decomposed and recovered, and the company’s operating performance will gradually improve.The remaining nine companies affected by the epidemic are Fuan Pharmaceutical, Yaoshi Technology, Wuwu Biology, Garden Biology, China Resources Sanjiu, Jiuqiang Biology, Beilu Pharmaceutical, Lepu Medical and Shutaishen.Among them, Beilu Pharmaceutical, Lepu Medical and Huaren Pharmaceutical said that the sales of drugs, implanted devices, medical services and other products have been significantly affected due to the continuous decline in hospital outpatient volume, testing volume, and engineering volume.Huaren Pharmaceutical is actively planning to add new business segments, new business contributes part of the profit, and the company returns large bank loans in 2019, financial expenses decreased compared with the same period last year, and the first quarter results are still expected to increase by 0% -20%.Beilu Pharmaceutical expects net profit to decrease by 10% -40% year-on-year; Lepu Medical expects net profit to increase by 28% -40% year-on-year.The largest change in net profit (-193.09%) Shu Taishen turned from a profit to a loss. The company said that sales activities in the first quarter were severely affected by the epidemic, and sales revenue and profits dropped significantly, coupled with an increase in research and development progress, resulting in poor first quarter results.Editor Yue Qingxiu proofreading Li Xiangling